.Expert consensus on integrated traditional Chinese and western medicine in the treatment of early⁃stage Parkinson’s disease (2021)[J].Shanghai Journal of Traditional Chinese Medicine,2022,56(1):1-6.
.Expert consensus on integrated traditional Chinese and western medicine in the treatment of early⁃stage Parkinson’s disease (2021)[J].Shanghai Journal of Traditional Chinese Medicine,2022,56(1):1-6. DOI: 10.16305/j.1007-1334.2021.2110003.
Expert consensus on integrated traditional Chinese and western medicine in the treatment of early⁃stage Parkinson’s disease (2021)
Parkinson’s disease (PD) is a degenerative disease of the central nervous system that commonly affects the middle-aged and elderly people. It is necessary to develop a long-term treatment strategy as patients diagnosed with PD have an average life expectancy of 17 years. Moreover, PD progresses rapidly in the early stage, and no sufficient evidence has been provided to prove that there is a single treatment or drug that can slow down the progression. Therefore, it is more significant to standardize the treatment of early-stage PD. Traditional Chinese medicine (TCM) is one of the most frequently used therapies for early-stage PD, and recent clinical studies have confirmed the efficacy enhancing, toxicity reducing and neuroprotective effects of integrated traditional Chinese and western medicine in the treatment of early PD. The Neurology Branch of the Shanghai Association of Chinese Medicine invited Chinese experts in the field of Chinese and western medicine for the treatment of Parkinson’s disease to reach an expert consensus on the integrated traditional Chinese and western medicine treatment of early-stage Parkinson’s disease for the purpose of providing reference for clinicians in the clinical treatment of early-stage Parkinson’s disease.
关键词
帕金森病早期颤证中西医结合诊断与治疗专家共识
Keywords
Parkinson’s diseaseearly stagetremor syndromeintegrated traditional Chinese and western medicinediagnosis and treatmentexpert consensus
references
ZHANG Z X, ROMAN G C, HONG Z, et al. Parkinson’s disease in China: prevalence in Beijing, Xian, and Shanghai[J]. Lancet, 2005, 365(9459): 595-597.
SCHAPIRA A H V . Treatment options in the modern management of Parkinson disease[J]. Arch Neurol, 2007, 64(8): 1083-1088.
ARMSTRONG M J, OKUN M S. Diagnosis and treatment of Parkinson disease: a review[J]. JAMA, 2020, 323(6): 548-560.
FOX S H, KATZENSCHLAGER R, LIM S Y, et al. The movement disorder society evidence-based medicine review update: Treatments for the motor symptoms of Parkinson disease[J]. Mov Disord, 2011, 26(Suppl 3): S2-S41.
KLEINMAN M, FRANK S. Epidemiology and clinical diagnosis of Parkinson disease[J]. PET Clinics, 2013, 8(4): 447-458.
LANGE R, ERBGUTH F. Parkinson’s disease in the elderly[J]. Z Gerontol Geriatr, 2017, 50(6): 547-559.
WEI W, CHEN H Y, FAN W, et al. Chinese medicine for idiopathic Parkinson’s disease: A meta analysis of randomized controlled trials[J]. Chin J Integr Med, 2017, 23(1): 55-61.
BARONE P, ANTONINI A, COLOSIMO C, et al. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease[J]. Mov Disord, 2009, 24(11): 1641-1649.
LI S, DONG J, CHENG C, et al. Therapies for Parkinson’s diseases: alternatives to current pharmacological interventions[J]. J Neural Transm, 2016, 123(11): 1279-1299.
CHUA K K, WONG A, CHAN K W, et al. A randomized controlled trial of Chinese medicine on nonmotor symptoms in Parkinson’s disease[J/OL]. Parkinsons Dis, 2017[2021-06-18]. https://pubmed.ncbi.nlm.nih.gov/28630780/https://pubmed.ncbi.nlm.nih.gov/28630780/.
SEPPI K, WEINTRAUB D, COELHO M, et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease[J]. Mov Disord , 2011, 26(Suppl 3): S42-S80.
FERREIRA J J, KATZENSCHLAGER R, BLOEM B R, et al. Summary of the recommendations of the EFNS/MDS⁃ES review on therapeutic management of Parkinson’s disease[J]. Eur J Neurol, 2012, 20(1): 5-15.
SEPPI K, RAY C K, COELHO M, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review[J]. Mov Disord, 2019, 34(2): 180-198.
POSTUMA R B, BERG D, STERN M, et al. MDS clinical diagnostic criteria for Parkinson’s disease[J]. Mov Disord, 2015, 30(12): 1591-1601.
FERESHTEHNEJAD S M, ROMENETS S R, ANANG J B, et al. New clinical subtypes of Parkinson disease and their longitudinal progression: a prospective cohort comparison with other phenotypes[J]. JAMA Neurol, 2015, 72(8): 863-873.
BROCK P, FISHER J M, HAND A, et al. Highlighting the goals for Parkinson’s care: commentary on NICE Guidelines for Parkinson’s in Adults(NG71)[J]. Age Ageing, 2019, 48(3): 323-326.
ALBORGHETTI M, NICOLETTI F. Different generations of type-B monoamine oxidase inhibitors in Parkinson’s disease: from bench to bedside[J]. Curr Neuropharmacol, 2019, 17(9): 861-873.
CHOU K L, STACY M, SIMUNI T, et al. The spectrum of “off” in Parkinson’s disease: What have we learned over 40 years?[J]. Parkinsonism Relat Disord, 2018(51): 9-16.
RABINAK C A, NIRENBERG M J. Dopamine agonist withdrawal syndrome in Parkinson disease[J]. Arch Neurol, 2010, 67(1): 58-63.
PONDAL M, MARRAS C, MIYASAKI J, et al. Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic[J]. J Neurol Neurosurg Psychiatry, 2013, 84(2): 130-135.
ESPAY A J, LANG A E. Common myths in the use of levodopa in Parkinson disease: when clinical trials misinform clinical practice[J]. JAMA Neurol, 2017, 74(6): 633-634.
GRAY R, IVES N, RICK C, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial[J]. Lancet, 2014, 384(9949): 1196-1205.
DUCAN G W,KHOO T K,YARNALL A J,et al. Health-related quality of life in early Parkinson’s disease: the impact of nonmotor symptoms[J]. Mov Disord, 2014, 29(2): 195-202.
ALATRISTE-BOOTH V, RODNGUEZ-VIOLANTE M, CAMACHO-ORDONEZ A, et al. Prevalence and correlates of sleep disorders in Parkinson disease: a polysomnographic study[J]. Arq Neuropsiquiatr, 2015, 73(3): 241-245.
Interpretation of Expert Consensus on Diagnosis and Treatment of Cervical Spondylotic Myelopathy with Integrated Traditional Chinese and Western Medicine
Advances in the diagnosis and treatment of cirrhotic portal hypertension with integrated traditional Chinese and Western medicine
Review and commentary of refractory cirrhotic ascites with diagnosis and treatment of integrative medicine
Practical application and development of activating blood and resolving stasis treatment method for liver cirrhosis
Yuan Canxing’s staged treatment experience for Parkinson’s disease based on nourishing liver and kidney
Related Author
No data
Related Institution
Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Shanghai Clinical Key Laboratory of Traditional Chinese Medicine
Cell Biology Laboratory,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Institute of Liver Diseases, Shanghai Academy of Traditional Chinese Medicine
Key Laboratory of Liver and Kidney Diseases, Ministry of Education